Results 11 - 15 of 22 for: "treprostinil"
Refine your search:Drug Interactions  

treprostinil Injection
...name(s): In the U.S. Remodulin Available Dosage Forms: Solution Therapeutic Class: Antihypertensive Pharmacologic Class: Prostaglandin Uses For treprostinil Treprostinil belongs to a group of agents called prostaglandins. Prostaglandins occur naturally in the body and are involved in many biological...
Advanced Consumer Information (Micromedex) · More like this

Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
...and its wholly-owned subsidiary Lung Rx, Inc. today announced that data related to the four different routes of administration of the drug, treprostinil, for the treatment of pulmonary arterial hypertension will be presented at the annual meeting of the American Thoracic Society (ATS), to be...
Clinical Trial Results (FDA) · More like this

FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
...SILVER SPRING, Md., Nov. 17 /PRNewswire-FirstCall/ -- United Therapeutics Corporation announced today the results of the FREEDOM-C trial of oral treprostinil, a sustained-release formulation of treprostinil, in pulmonary arterial hypertension (PAH). Preliminary analysis demonstrates that the trial...
Clinical Trial Results (FDA) · More like this

Aradigm Completes Study of Inhaled Treprostinil with AERx Inhaler
HAYWARD, Calif.--(BUSINESS WIRE)--Nov 10, 2008 - Aradigm Corporation (OTCBB:ARDM) today announced the results of a clinical trial of inhaled treprostinil in Aradigm's palm-size AERx Essence(R) inhaler and receipt of $2.75 million, which includes the first milestone of $2 million and development...
Clinical Trial Results (FDA) · More like this

Inhaled Treprostinil New Drug Application Filed by FDA
...Lung Rx, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for inhaled treprostinil for the treatment of pulmonary arterial hypertension. The NDA will be subject to a standard review period of 10 months, with a targeted user...
New Drug Applications (FDA) · More like this

See also: Pulmonary Arterial Hypertension

Having trouble finding what you want?


MedNotes
Advertisement

(web9)